IMMU-106

Known as: monoclonal antibody IMMU-106 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2011
01220042011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
Review
2011
Review
2011
Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits… (More)
  • table I
  • table II
Is this relevant?
Review
2009
Review
2009
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell hyperactivity and defective T-cell function… (More)
Is this relevant?
Review
2008
Review
2008
For many years, alkylating agents and purine nucleoside analogs (PNA) have been considered the drug of choice for treatment of… (More)
Is this relevant?
2006
2006
7530 Background: The humanized anti-CD20 antibody, IMMU-106 (hA20), has similar murine CDRs to rituximab, but the remaining… (More)
Is this relevant?
2006
2006
2536 Background: Anti-CD20 and anti-CD22 monoclonal antibodies (MAbs) have been shown to have antitumor activity in non-Hodgkin's… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE A new humanized anti-CD20 monoclonal antibody (MAb), IMMU-106, was evaluated to elucidate its action as an antilymphoma… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?